Oren Livnat
Stock Analyst at HC Wainwright & Co.
(3.20)
# 1,095
Out of 4,681 analysts
133
Total ratings
42.5%
Success rate
3.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oren Livnat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Reiterates: Buy | $200 | $121.58 | +64.50% | 16 | Nov 22, 2024 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $9.68 | +106.61% | 8 | Nov 20, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Buy | $27 → $25 | $11.59 | +115.70% | 14 | Nov 13, 2024 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6 → $6.6 | $3.38 | +95.27% | 10 | Nov 11, 2024 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $94 | $57.87 | +62.43% | 11 | Nov 11, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Neutral | n/a | $1.28 | - | 11 | Nov 6, 2024 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $6 | $2.86 | +109.79% | 2 | Oct 22, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $47 → $50 | $31.33 | +59.59% | 8 | Sep 5, 2024 | |
| PCRX Pacira BioSciences | Maintains: Buy | $57 → $39 | $17.81 | +118.98% | 17 | Aug 12, 2024 | |
| CARA Cara Therapeutics | Downgrades: Neutral | n/a | $0.29 | - | 13 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $57 → $61 | $50.42 | +20.98% | 8 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $6.59 | +13.81% | 6 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $8 | $1.32 | +506.06% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $60 | $4.30 | +1,283.72% | 5 | Aug 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $252 → $198 | $2.88 | +6,775.00% | 2 | May 7, 2021 |
Jazz Pharmaceuticals
Nov 22, 2024
Reiterates: Buy
Price Target: $200
Current: $121.58
Upside: +64.50%
Zevra Therapeutics
Nov 20, 2024
Reiterates: Buy
Price Target: $20
Current: $9.68
Upside: +106.61%
Avadel Pharmaceuticals
Nov 13, 2024
Maintains: Buy
Price Target: $27 → $25
Current: $11.59
Upside: +115.70%
Xeris Biopharma Holdings
Nov 11, 2024
Maintains: Buy
Price Target: $6 → $6.6
Current: $3.38
Upside: +95.27%
ANI Pharmaceuticals
Nov 11, 2024
Reiterates: Buy
Price Target: $94
Current: $57.87
Upside: +62.43%
Verrica Pharmaceuticals
Nov 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.28
Upside: -
Trevi Therapeutics
Oct 22, 2024
Reiterates: Buy
Price Target: $6
Current: $2.86
Upside: +109.79%
Collegium Pharmaceutical
Sep 5, 2024
Maintains: Buy
Price Target: $47 → $50
Current: $31.33
Upside: +59.59%
Pacira BioSciences
Aug 12, 2024
Maintains: Buy
Price Target: $57 → $39
Current: $17.81
Upside: +118.98%
Cara Therapeutics
Jun 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.29
Upside: -
May 13, 2024
Maintains: Buy
Price Target: $57 → $61
Current: $50.42
Upside: +20.98%
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $6.59
Upside: +13.81%
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $1.32
Upside: +506.06%
Aug 26, 2021
Maintains: Buy
Price Target: $43 → $60
Current: $4.30
Upside: +1,283.72%
May 7, 2021
Maintains: Buy
Price Target: $252 → $198
Current: $2.88
Upside: +6,775.00%